LIGAND PHARMACEUTICALS INC — Director's Dealing 2018

Aug 18, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2018-08-16

Reporting Person: Davis Todd C (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-16	Common Stock	S	5833	$239.9289	Disposed	48223	Direct
2018-08-17	Common Stock	S	3167	$239.5	Disposed	45056	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $239.8845 to $240.3250, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.